Literature DB >> 11038435

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects.

N B Modi1, B Wang, W T Hu, S K Gupta.   

Abstract

The effect of a high-fat meal on the pharmacokinetics of OROS(R) (methylphenidate HCl), an osmotic controlled-release formulation of methylphenidate HCl, was investigated in healthy subjects. Mean peak methylphenidate plasma concentrations occurred slightly later and peak methylphenidate plasma concentrations and AUC values were slightly higher (approximately 10-30%) in the presence of food than in the absence of food. There was no difference in the plasma elimination half-life of methylphenidate between the fed and fasted state. Similarly, peak concentrations and AUC values for alpha-phenyl-2-piperidine acetic acid (PPA; ritalinic acid), the major metabolite of methylphenidate, were slightly higher in the presence of food than in its absence. The 90% confidence interval (CI) for the treatment ratio (fed/fasted) for C(max) was 120.6%-140. 0% for the 18-mg dose and 105.4-119.3% for a 36-mg dose. The 90% CI for the treatment ratio for AUC(infinity) was 114.6-125.7% for the 18-mg dose and 115.1-124.6% for the 36-mg dose. PPA levels were measured following the 18-mg dose and the 90% CI of the treatment ratio was 106.8-115.4% for C(max) and 97.9-103.6% for AUC(infinity). These results indicate the absence of dose dumping from OROS (methylphenidate HCl) in the presence of food. Food does not impede drug absorption and OROS (methylphenidate HCl) may be administered in the fed or fasted state. There were no differences in the adverse event profile between the fed and fasted state. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038435     DOI: 10.1002/1099-081x(200001)21:1<23::aid-bdd212>3.0.co;2-v

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  15 in total

1.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

Review 2.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

3.  Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Authors:  Liang Li; Yaning Wang; Ramana S Uppoor; Mehul U Mehta; Tiffany Farchione; Mitchell V Mathis; Hao Zhu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-18       Impact factor: 2.745

4.  Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches.

Authors:  Roberto Gomeni; Françoise Bressolle-Gomeni
Journal:  AAPS J       Date:  2019-12-09       Impact factor: 4.009

5.  Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.

Authors:  Gayatri Sathyan; Roger R Dmochowski; Rodney A Appell; Cindy Guo; Suneel K Gupta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.

Authors:  B S Schug; E Brendel; E Chantraine; D Wolf; W Martin; R Schall; H H Blume
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

7.  Effects of food on the pharmacokinetics of methylphenidate.

Authors:  K K Midha; G McKay; M J Rawson; E D Korchinski; J W Hubbard
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick; C Lindsay DeVane; Linda Pestreich; James Lee; Yanfeng Wang; Rafael Muniz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.

Authors:  Mark L Wolraich; Melissa A Doffing
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag).

Authors:  Elisabeth Schapperer; Heike Daumann; Stéphane Lamouche; Ursula Thyroff-Friesinger; François Viel; Werner Weitschies
Journal:  Pharmacol Res Perspect       Date:  2015-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.